JP2024539928A5 - - Google Patents

Info

Publication number
JP2024539928A5
JP2024539928A5 JP2024524401A JP2024524401A JP2024539928A5 JP 2024539928 A5 JP2024539928 A5 JP 2024539928A5 JP 2024524401 A JP2024524401 A JP 2024524401A JP 2024524401 A JP2024524401 A JP 2024524401A JP 2024539928 A5 JP2024539928 A5 JP 2024539928A5
Authority
JP
Japan
Prior art keywords
cacng1
nucleic acid
human animal
acid sequence
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539928A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079336 external-priority patent/WO2023081847A1/en
Publication of JP2024539928A publication Critical patent/JP2024539928A/ja
Publication of JP2024539928A5 publication Critical patent/JP2024539928A5/ja
Pending legal-status Critical Current

Links

JP2024524401A 2021-11-04 2022-11-04 改変ｃａｃｎｇ１遺伝子座を含む非ヒト動物 Pending JP2024539928A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163275582P 2021-11-04 2021-11-04
US63/275,582 2021-11-04
PCT/US2022/079336 WO2023081847A1 (en) 2021-11-04 2022-11-04 Non-human animals comprising a modified cacng1 locus

Publications (2)

Publication Number Publication Date
JP2024539928A JP2024539928A (ja) 2024-10-31
JP2024539928A5 true JP2024539928A5 (https=) 2025-11-10

Family

ID=84520015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524401A Pending JP2024539928A (ja) 2021-11-04 2022-11-04 改変ｃａｃｎｇ１遺伝子座を含む非ヒト動物

Country Status (9)

Country Link
US (1) US20250017183A1 (https=)
EP (1) EP4426107A1 (https=)
JP (1) JP2024539928A (https=)
KR (1) KR20240107104A (https=)
CN (1) CN118488784A (https=)
AU (1) AU2022381205A1 (https=)
CA (1) CA3231899A1 (https=)
IL (1) IL312505A (https=)
WO (1) WO2023081847A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121568720A (zh) * 2023-07-10 2026-02-24 瑞泽恩制药公司 抗人类cacng1抗体-药物缀合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8587598A (en) 1997-07-26 1999-02-16 Wisconsin Alumni Research Foundation Trans-species nuclear transfer
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
AUPR451401A0 (en) 2001-04-20 2001-05-24 Monash University A method of nuclear transfer
US7612250B2 (en) 2002-07-29 2009-11-03 Trustees Of Tufts College Nuclear transfer embryo formation method
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
GB0517916D0 (en) * 2005-09-02 2005-10-12 Paradigm Therapeutics Ltd Ion channel
CN101117633B (zh) 2006-08-03 2011-07-20 上海交通大学附属儿童医院 一种细胞核移植方法
JP2011517838A (ja) 2008-04-11 2011-06-16 ユーティーシー パワー コーポレイション マニホルド・サンプを備えたバイポーラプレートおよび燃料電池
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
SG11201406547YA (en) 2012-04-25 2014-11-27 Regeneron Pharma Nuclease-mediated targeting with large targeting vectors
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
WO2014033644A2 (en) 2012-08-28 2014-03-06 Novartis Ag Methods of nuclease-based genetic engineering
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
MX384291B (es) 2013-02-20 2025-03-14 Regeneron Pharma Modificación genética de ratas.
KR102170502B1 (ko) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
DK3386534T3 (da) * 2015-12-08 2020-11-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
DK3635009T3 (da) * 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer

Similar Documents

Publication Publication Date Title
CN112040769B (zh) 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途
CN105578876B (zh) 制备表达hlai类的非人动物的方法
JPH06507782A (ja) アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
CN113105555B (zh) Mhc分子人源化的非人动物的构建方法及应用
CN1491624A (zh) 经修饰的生物材料
JP6777671B2 (ja) 条件付きＡｃｖｒ１突然変異遺伝子をもつ齧歯類
CN116114656B (zh) 一种红斑狼疮小鼠模型的构建方法及应用
JP2008541781A5 (https=)
JP2024539928A5 (https=)
WO2014117045A2 (en) Animal models of duchenne muscular dystrophy
JP2000509606A (ja) Ｌｉｆ過剰発現および／またはｇｈ発現低下に伴う下垂体障害のトランスジェニック非ヒト動物モデルおよび該状態の治療薬の試験を目的とするその使用
Chen et al. Overexpressing dominant-negative FGFR2-IIIb impedes lung branching morphogenesis in pigs
CN112292030A (zh) 进行性骨化性纤维发育不良的啮齿类动物模型
WO2022057903A1 (en) Genetically modified non-human animal with human or chimeric glp1r
JP2003513645A (ja) メラノコルチン−３レセプター欠失細胞、非ヒトトランスジェニック動物及び体重を調節する化合物の選択方法
CN108070614A (zh) 人源化基因改造动物模型的制备方法及应用
JP5099856B2 (ja) 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法
JPH08511688A (ja) Ｅｃ−ｓｏｄの形質転換生産
WO2002034041A1 (en) Senescence marker protein 30-defective nonhuman animal, antibody and method of constructing the same
CN106866813A (zh) 人源化基因编辑哺乳动物的制备方法及其用途
CN121555569A (zh) 一种用于内源Col1a1+细胞谱系示踪的动物模型及构建方法和应用
US20070072296A1 (en) C/EBPalpha gene targeting constructs and uses thereof
CN119932110A (zh) Kit基因修饰的非人动物的制备方法和应用
CN120400248A (zh) 一种kif1a基因点突变小鼠模型的构建方法及其应用
HK1256239B (en) Rodents with conditional acvr1 mutant alleles